Search

Your search keyword '"Greenberg, J.D."' showing total 33 results
Start Over Author "Greenberg, J.D." Publication Year Range Last 10 years
33 results on '"Greenberg, J.D."'

2. The National Psoriasis Foundation psoriasis treatment targets in real‐world patients: prevalence and association with patient‐reported outcomes in the Corrona Psoriasis Registry

Author

Merola, J.F., primary, Perez Chada, L.M., additional, Siegel, M., additional, Bagel, J., additional, Evans, C., additional, Lockshin, B., additional, Mason, M., additional, Guo, N., additional, McLean, R.R., additional, Greenberg, J.D., additional, and Van Voorhees, A.S., additional

Published
2020
Full Text
View/download PDF

3. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US ‐based Corrona Psoriasis Registry

Author

Mease, P.J., primary, Palmer, J.B., additional, Hur, P., additional, Strober, B.E., additional, Lebwohl, M., additional, Karki, C., additional, Reed, G.W., additional, Etzel, C.J., additional, Greenberg, J.D., additional, and Helliwell, P. S., additional

Published
2019
Full Text
View/download PDF

7. The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis

Author

Cui, J., Diogo, D., Stahl, E.A., Canhao, H., Mariette, X., Greenberg, J.D., Okada, Y., Pappas, D.A., Fulton, R.S., Tak, P.P., Nurmohamed, M.T., Lee, A., Larson, D.E., Kurreeman, F., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Mardis, E.R., Horst-Bruinsma, I.E. van der, Wolbink, G.J., Gregersen, P.K., Kremer, J.M., Crusius, J.B.A., Vries, N. de, Huizinga, T.W.J., Fonseca, J.E., Miceli-Richard, C., Karlson, E.W., Coenen, M.J.H., Barton, A., Plenge, R.M., and Raychaudhuri, S.

Published
2017

11. Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis

Author

Cui, J., Diogo, D., Stahl, E.A., Canhao, H., Mariette, X., Greenberg, J.D., Okada, Y., Pappas, D.A., Fulton, R.S., Tak, P.P., Nurmohamed, M.T., Lee, A., Larson, D.E., Kurreeman, F., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Mardis, E.R., Horst-Bruinsma, I.E., Wolbink, G.J., Gregersen, P.K., Kremer, J.M, Crusius, J.B.A., Vries, N. de, Huizinga, T.W.J., Fonseca, J.E., Miceli-Richard, C., Karlson, E.W., Coenen, M.J.H., Barton, A., Plenge, R.M., Raychaudhuri, S., Cui, J., Diogo, D., Stahl, E.A., Canhao, H., Mariette, X., Greenberg, J.D., Okada, Y., Pappas, D.A., Fulton, R.S., Tak, P.P., Nurmohamed, M.T., Lee, A., Larson, D.E., Kurreeman, F., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Mardis, E.R., Horst-Bruinsma, I.E., Wolbink, G.J., Gregersen, P.K., Kremer, J.M, Crusius, J.B.A., Vries, N. de, Huizinga, T.W.J., Fonseca, J.E., Miceli-Richard, C., Karlson, E.W., Coenen, M.J.H., Barton, A., Plenge, R.M., and Raychaudhuri, S.

Abstract

Item does not contain fulltext, OBJECTIVE: In many rheumatoid arthritis (RA) patients, disease is controlled with anti-tumor necrosis factor (anti-TNF) biologic therapies. However, in a significant number of patients, the disease fails to respond to anti-TNF therapy. We undertook the present study to examine the hypothesis that rare and low-frequency genetic variants might influence response to anti-TNF treatment. METHODS: We sequenced the coding region of 750 genes in 1,094 RA patients of European ancestry who were treated with anti-TNF. After quality control, 690 genes were included in the analysis. We applied single-variant association and gene-based association tests to identify variants associated with anti-TNF treatment response. In addition, given the key mechanistic role of TNF, we performed gene set analyses of 27 TNF pathway genes. RESULTS: We identified 14,420 functional variants, of which 6,934 were predicted as nonsynonymous 2,136 of which were further predicted to be "damaging." Despite the fact that the study was well powered, no single variant or gene showed study-wide significant association with change in the outcome measures disease activity or European League Against Rheumatism response. Intriguingly, we observed 3 genes, of 27 with nominal signals of association (P < 0.05), that were involved in the TNF signaling pathway. However, when we performed a rigorous gene set enrichment analysis based on association P value ranking, we observed no evidence of enrichment of association at genes involved in the TNF pathway (Penrichment = 0.15, based on phenotype permutations). CONCLUSION: Our findings suggest that rare and low-frequency protein-coding variants in TNF signaling pathway genes or other genes do not contribute substantially to anti-TNF treatment response in patients with RA.

Published
2017

26. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits

Author

Diogo, D., Bastarache, L., Liao, K.P., Graham, R.R., Fulton, R.S., Greenberg, J.D., Eyre, S., Bowes, J., Cui, J., Lee, A., Pappas, D.A., Kremer, H., Barton, A., Coenen, M.J.H., Franke, B., Kiemeney, L.A.L.M., Mariette, X., Richard-Miceli, C., Canhao, H., Fonseca, J.E., Vries, N. de, Tak, P.P., Crusius, J.B.A., Nurmohamed, M.T., Kurreeman, F., Mikuls, T.R., Okada, Y., Stahl, E.A., Larson, D.E., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Kosoy, R., Ransom, M., Bhangale, T.R., Ortmann, W., Cagan, A., Gainer, V., Karlson, E.W., Kohane, I., Murphy, S.N., Martin, J., Zhernakova, A., Klareskog, L., Padyukov, L., Worthington, J., Mardis, E.R., Seldin, M.F., Gregersen, P.K., Behrens, T., Raychaudhuri, S., Denny, J.C., Plenge, R.M., Diogo, D., Bastarache, L., Liao, K.P., Graham, R.R., Fulton, R.S., Greenberg, J.D., Eyre, S., Bowes, J., Cui, J., Lee, A., Pappas, D.A., Kremer, H., Barton, A., Coenen, M.J.H., Franke, B., Kiemeney, L.A.L.M., Mariette, X., Richard-Miceli, C., Canhao, H., Fonseca, J.E., Vries, N. de, Tak, P.P., Crusius, J.B.A., Nurmohamed, M.T., Kurreeman, F., Mikuls, T.R., Okada, Y., Stahl, E.A., Larson, D.E., Deluca, T.L., O'Laughlin, M., Fronick, C.C., Fulton, L.L., Kosoy, R., Ransom, M., Bhangale, T.R., Ortmann, W., Cagan, A., Gainer, V., Karlson, E.W., Kohane, I., Murphy, S.N., Martin, J., Zhernakova, A., Klareskog, L., Padyukov, L., Worthington, J., Mardis, E.R., Seldin, M.F., Gregersen, P.K., Behrens, T., Raychaudhuri, S., Denny, J.C., and Plenge, R.M.

Abstract

Contains fulltext : 154077.pdf (publisher's version ) (Open Access), Despite the success of genome-wide association studies (GWAS) in detecting a large number of loci for complex phenotypes such as rheumatoid arthritis (RA) susceptibility, the lack of information on the causal genes leaves important challenges to interpret GWAS results in the context of the disease biology. Here, we genetically fine-map the RA risk locus at 19p13 to define causal variants, and explore the pleiotropic effects of these same variants in other complex traits. First, we combined Immunochip dense genotyping (n = 23,092 case/control samples), Exomechip genotyping (n = 18,409 case/control samples) and targeted exon-sequencing (n = 2,236 case/controls samples) to demonstrate that three protein-coding variants in TYK2 (tyrosine kinase 2) independently protect against RA: P1104A (rs34536443, OR = 0.66, P = 2.3 x 10(-21)), A928V (rs35018800, OR = 0.53, P = 1.2 x 10(-9)), and I684S (rs12720356, OR = 0.86, P = 4.6 x 10(-7)). Second, we show that the same three TYK2 variants protect against systemic lupus erythematosus (SLE, Pomnibus = 6 x 10(-18)), and provide suggestive evidence that two of the TYK2 variants (P1104A and A928V) may also protect against inflammatory bowel disease (IBD; P(omnibus) = 0.005). Finally, in a phenome-wide association study (PheWAS) assessing >500 phenotypes using electronic medical records (EMR) in >29,000 subjects, we found no convincing evidence for association of P1104A and A928V with complex phenotypes other than autoimmune diseases such as RA, SLE and IBD. Together, our results demonstrate the role of TYK2 in the pathogenesis of RA, SLE and IBD, and provide supporting evidence for TYK2 as a promising drug target for the treatment of autoimmune diseases.

Published
2015

30. AB1157 Characteristics of a US Psoriatic Arthritis/Spondyloarthritis Cohort: Baseline Data from the Corrona PSA/SPA Registry

Author

Mease, P.J., primary, Etzel, C.J., additional, Kremer, J.M., additional, Deveikis, S., additional, Li, Y., additional, O'Connor, J., additional, Kavanaugh, A., additional, Ruderman, E., additional, Curtis, J.R., additional, Ritchlin, C.T., additional, van der Heijde, D., additional, Solomon, D., additional, and Greenberg, J.D., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results